Latest Insider Transactions at Opiant Pharmaceuticals, Inc. (OPNT)
This section provides a real-time view of insider transactions for Opiant Pharmaceuticals, Inc. (OPNT). The data is sourced from Form 4 filings with the SEC, which are filed by insiders of OPIANT PHARMACEUTICALS, INC. to disclose their transactions in the company's securities. By reviewing this information, investors can gain insights into the trading activity of OPIANT PHARMACEUTICALS, INC.'s insiders and make more informed investment decisions.
Insider Transaction List
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Aug 19
2021
|
Thomas T. Thomas Director |
SELL
Open market or private sale
|
Direct |
1,000
-7.41%
|
$16,000
$16.23 P/Share
|
|
Aug 16
2021
|
David D O'Toole Chief Financial Officer |
BUY
Open market or private purchase
|
Direct |
600
+2.46%
|
$9,000
$15.38 P/Share
|
|
Jul 19
2021
|
Matthew R. Ruth Chief Commercial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
15,000
+50.0%
|
-
|
|
Jun 15
2021
|
Craig A Collard Director |
BUY
Grant, award, or other acquisition
|
Direct |
2,000
+33.33%
|
-
|
|
Jun 15
2021
|
Masuoka K. Lorianne Director |
BUY
Grant, award, or other acquisition
|
Direct |
2,000
+50.0%
|
-
|
|
Jun 15
2021
|
Gabrielle Alison Silver Director |
BUY
Grant, award, or other acquisition
|
Direct |
2,000
+9.6%
|
-
|
|
Jun 15
2021
|
Ann L. Mac Dougall Director |
BUY
Grant, award, or other acquisition
|
Direct |
2,000
+7.94%
|
-
|
|
Jun 15
2021
|
Richard J Daly Director |
BUY
Grant, award, or other acquisition
|
Direct |
2,000
+25.64%
|
-
|
|
Jun 15
2021
|
Thomas T. Thomas Director |
BUY
Grant, award, or other acquisition
|
Direct |
2,000
+22.22%
|
-
|
|
May 13
2021
|
Ann L. Mac Dougall Director |
BUY
Exercise of conversion of derivative security
|
Direct |
341
+1.58%
|
$3,410
$10.0 P/Share
|
|
May 13
2021
|
Gabrielle Alison Silver Director |
BUY
Exercise of conversion of derivative security
|
Direct |
365
+2.12%
|
$3,650
$10.0 P/Share
|
|
Mar 17
2021
|
Gabrielle Alison Silver Director |
SELL
Open market or private sale
|
Direct |
7,157
-30.28%
|
$78,727
$11.07 P/Share
|
|
Mar 17
2021
|
Gabrielle Alison Silver Director |
BUY
Exercise of conversion of derivative security
|
Direct |
7,886
+25.02%
|
$78,860
$10.0 P/Share
|
|
Mar 17
2021
|
Ann L. Mac Dougall Director |
SELL
Open market or private sale
|
Direct |
6,606
-24.07%
|
$72,666
$11.07 P/Share
|
|
Mar 17
2021
|
Ann L. Mac Dougall Director |
BUY
Exercise of conversion of derivative security
|
Direct |
7,279
+20.96%
|
$72,790
$10.0 P/Share
|
|
Mar 16
2021
|
Gabrielle Alison Silver Director |
SELL
Open market or private sale
|
Direct |
1,949
-11.01%
|
$21,439
$11.5 P/Share
|
|
Mar 16
2021
|
Gabrielle Alison Silver Director |
BUY
Exercise of conversion of derivative security
|
Direct |
2,231
+11.19%
|
$22,310
$10.0 P/Share
|
|
Mar 16
2021
|
Ann L. Mac Dougall Director |
SELL
Open market or private sale
|
Direct |
1,949
-8.81%
|
$21,439
$11.5 P/Share
|
|
Mar 16
2021
|
Ann L. Mac Dougall Director |
BUY
Exercise of conversion of derivative security
|
Direct |
2,231
+9.16%
|
$22,310
$10.0 P/Share
|
|
Mar 15
2021
|
Gabrielle Alison Silver Director |
SELL
Open market or private sale
|
Direct |
3,900
-20.14%
|
$42,900
$11.64 P/Share
|
|
Mar 15
2021
|
Gabrielle Alison Silver Director |
BUY
Exercise of conversion of derivative security
|
Direct |
4,518
+18.92%
|
$45,180
$10.0 P/Share
|
|
Mar 15
2021
|
Ann L. Mac Dougall Director |
SELL
Open market or private sale
|
Direct |
5,600
-21.98%
|
$61,600
$11.63 P/Share
|
|
Mar 15
2021
|
Ann L. Mac Dougall Director |
BUY
Exercise of conversion of derivative security
|
Direct |
6,483
+20.28%
|
$64,830
$10.0 P/Share
|
|
Mar 05
2021
|
Gabrielle Alison Silver Director |
BUY
Exercise of conversion of derivative security
|
Direct |
8,334
+35.95%
|
$83,340
$10.0 P/Share
|
|
Feb 11
2021
|
Ann L. Mac Dougall Director |
BUY
Exercise of conversion of derivative security
|
Direct |
7,000
+26.92%
|
$70,000
$10.0 P/Share
|
|
Jan 26
2021
|
Brian Gorman |
BUY
Grant, award, or other acquisition
|
Direct |
6,774
+14.74%
|
-
|
|
Jan 26
2021
|
Phil Skolnick Chief Scientific Officer |
BUY
Grant, award, or other acquisition
|
Direct |
8,198
+29.57%
|
-
|
|
Jan 26
2021
|
Mark Jason Heath Ellison Chief Development Officer |
BUY
Grant, award, or other acquisition
|
Direct |
7,636
+45.71%
|
-
|
|
Jan 26
2021
|
David D O'Toole Chief Financial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
7,850
+15.48%
|
-
|
|
Jan 26
2021
|
Roger Crystal Chief Executive Officer |
BUY
Grant, award, or other acquisition
|
Direct |
19,416
+20.03%
|
-
|